Unknown

Dataset Information

0

Biomaterial-enabled therapeutic modulation of cGAS-STING signaling for enhancing antitumor immunity.


ABSTRACT: cGAS-STING signaling is a central component in the therapeutic action of most existing cancer therapies. The accumulated knowledge of tumor immunoregulatory network in recent years has spurred the development of cGAS-STING agonists for tumor treatment as an effective immunotherapeutic strategy. However, the clinical translation of these agonists is thus far unsatisfactory because of the low immunostimulatory efficacy and unrestricted side effects under clinically relevant conditions. Interestingly, the rational integration of biomaterial technology offers a promising approach to overcome these limitations for more effective and safer cGAS-STING-mediated tumor therapy. Herein, we first outline the cGAS-STING signaling axis and generally discuss its association with tumors. We then symmetrically summarize the recent progress in those biomaterial-based cGAS-STING agonism strategies to generate robust antitumor immunity, categorized by the chemical nature of those cGAS-STING stimulants and carrier substrates. Finally, a perspective is provided to discuss the existing challenges and potential opportunities in cGAS-STING modulation for tumor therapy.

SUBMITTER: Liu Y 

PROVIDER: S-EPMC10362396 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Biomaterial-enabled therapeutic modulation of cGAS-STING signaling for enhancing antitumor immunity.

Liu Yingqi Y   Fei Yang Y   Wang Xuan X   Yang Bingbing B   Li Menghuan M   Luo Zhong Z  

Molecular therapy : the journal of the American Society of Gene Therapy 20230331 7


cGAS-STING signaling is a central component in the therapeutic action of most existing cancer therapies. The accumulated knowledge of tumor immunoregulatory network in recent years has spurred the development of cGAS-STING agonists for tumor treatment as an effective immunotherapeutic strategy. However, the clinical translation of these agonists is thus far unsatisfactory because of the low immunostimulatory efficacy and unrestricted side effects under clinically relevant conditions. Interesting  ...[more]

Similar Datasets

| S-EPMC11430494 | biostudies-literature
| S-EPMC11303708 | biostudies-literature
| S-EPMC7508354 | biostudies-literature
| S-EPMC10538367 | biostudies-literature
| S-EPMC8741839 | biostudies-literature
| S-EPMC5547907 | biostudies-literature
| S-EPMC9705441 | biostudies-literature
| S-EPMC10642193 | biostudies-literature
2024-09-27 | GSE251940 | GEO
| S-EPMC10132258 | biostudies-literature